Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

Naltrexone is an opioid receptor antagonist approved for the treatment of alcohol and opioid use disorders at doses of 50–150 mg/d. Naltrexone has also been prescribed at much lower doses (3–6 mg/d) for the off-label treatment of inflammation and pain. Currently, a compelling mechanistic explanation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:eNeuro
Main Authors: Metz, Marissa J., Daimon, Caitlin M., Hentges, Shane T.
Formato: Artigo
Idioma:Inglês
Publicado em: Society for Neuroscience 2021
Assuntos:
Research Article: Negative Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211470/
https://ncbi.nlm.nih.gov/pubmed/34031099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1523/ENEURO.0087-21.2021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados